|
SCP
Vitalife Portfolio |
 |
|
Pocared Diagnostics, Ltd.
Pocared has developed an innovative diagnostic
system that provides physicians with real-time detection and
identification of pathogens. This system is automated,
rapid, compact, user-friendly and does not require the use
of reagents. Pocared's technological platform may be used
to address a wide range of medical and industrial diagnostic
applications. The company's first application, expected to
be launched during the next 24 months, will target medical
IVD. Pocared is located in Petach Tikvah, Israel.
|
 |
|
NiTi
Surgical Solutions, Ltd.
http://www.nitisurgical.com/
NiTi Surgical Solutions has developed and is
commercializing a new generation of surgical devices that
yield excellent anastomotic tissue closure without the use
of staples, based on clips and rings made of the “shape
memory” alloy, Nitinol. Its line of clinically tested
instruments represent a major advance in tissue closure for
gastrointestinal (GI) surgery. NiTi is located in Netanya,
Israel.
|
 |
|
Regentis Biomaterials, Ltd.
www.regentis.co.il
is a medical material development company that is
focused on commercializing its patent-applied Gelrin
Platform Technology for bone, spine and cartilage
repair.
|
|
VITALIFE PORTFOLIO
|
 |
|
MediGuide
www.mediguide.co.il
develops and provides intra - body navigation
solutions for a wide range of medical applications.
The GIVUS innovative technology - 3D Guided-IVUS
system enables quantitative 3D visualization of
coronary vessels, as well as real-time CI devices
navigation within the coronary arteries.
|
 |
|
SightLine Technologies Ltd.
www.sightline.co.il
is a dynamic Israel-based company specializing in
unique video endoscopic systems for minimally
invasive procedures. The company develops and
markets innovative medical devices and accessories
for a wide range of diagnostic and therapeutic
procedures.
Acquired by Stryker Corporation
(NYSE:SYK) |
 |
|
Procognia
www.procognia.com
has been created
to deliver technologies that extract the maximum
value from protein-based pharmaceuticals. Our
initial range of U-c technologies, due to be
launched next year, exploit new glycoanalysis
techniques that can be used throughout drug
discovery, development and manufacture. Each product
under development has the potential to yield
significantly higher levels of information, in
dramatically reduced timescales, employing fewer
resources.
|
 |
|
Florence Medical
www.florencemedical.com
develops
and markets advanced generations systems within the
cardiovascular arena to evaluate the homodynamic
status of diseased arteries and provide further
clinical information in the diagnoses and treatment
of both coronary and periartery disease.
|
 |
|
TransPharma
www.transpharma-medical.com
specializes in
the development of novel, transdermal drug delivery
systems. These systems enable the delivery as well
as improve the effectiveness of small molecules,
proteins, hormones, vaccines and other
macromolecules
|
 |
|
Denx Ltd.
www.denx.com
Develops and
markets the world's most advanced image-guided
technology for dental training and clinical
implementation. Denx's exclusive 3D graphics and
real-time image processing are used by leading
dental institutions in the U.S., Europe and Asia for
maximum precision and effectiveness.
|
 |
|
Medson
develops ultrasound-based equipment designed to detect and
image abnormalities in bones, cartilage and
ligaments.
|
 |
|
CanFite
www.canfite.com
is a
biopharmaceutical company that develops drugs based
on a platform technology. Can-Fite's platform
technology permits targeting major human diseases
including cancer, viral infections, diabetes type
II, Alzheimer's disease and others. All of Can-Fite's
drugs are small molecules that can be administered
orally as pills or capsules. Can-Fite's lead drug,
CF101, is in clinical trials and is being developed
as a drug for use in cancer treatment. CF 101 and
other drugs in Can-Fite's portfolio, has a highly
specific anti-cancer activity and unlike most other
drugs that are used in cancer treatment today, is
devoid of toxicity and when administered in
combination with chemotherapy, yields a higher
anti-cancer effect than chemotherapy alone and
reduces some of the sever toxic side effects of the
chemotherapeutic treatment.
IPO Tel Aviv Stock Exchange (TASE:CFBI)
|
 |
|
Deep Breeze
www.deepbreeze.com
is developing
a revolutionary medical imaging device, the
PALIScope, which will offer the physician a
valuable, radiation-free, real-time, diagnostic lung
imaging.
|
 |
|
Trig Medical Inc.
www.trigmed.com
is
developing innovative computerized systems for
monitoring labor. The company's first product,
DM1000 provides real-time visual information on the
exact position of the baby along the birth canal,
the effectiveness of the uterine contractions and
the uterine cervix opening. The DM1000's unique
capability will have a tremendous impact on the
efficiently and safety in the delivery room and the
quality of care delivered.
|
 |
|
QuantomiX
www.quantomix.com
develops and
markets capsules that enable on-line accurate
analysis of wet cells and tissue biopsies in
research patient care and drug discovery. The
company has solved a 50-year-old problem of direct
imaging of hydrated samples in an electron
microscope.The company was founded in 2001 to
commercialize its breakthrough technology. With the
Quantomix QXTM capsule product line, wet
samples,including cells and tissues biopsies, can
now be examined immediately and accurately. The
products are at a Beta development stage in leading
research institutes in the US and Israel, the
platform is set to be marketed first in the United
States and then in Europe and Japan.
|
 |
|
Beta-O2 Technologies Ltd.
is a medical device biotechnology company,
developing a proprietary implantable artificial
pancreas, the BO2TM.The device is designed for
treatment of Type 1 diabetes, and a subgroup of Type
2 diabetes. The company is located in Petach-Tikva,
Israel.
|
 |
|
TEIC's
www.teic.co.il
goal is to create
and support zero-stage start-up companies that will
produce innovative high-tech products and
technologies for tomorrow's markets. TEIC assists
zero-stage, technology-based start-ups develop
products and innovative technologies for tomorrow's
markets. The incubator specializes in supporting and
promoting technological enterprises rom initial
concept and development and implementation to
profitable commercial venture. TEIC was established
in 1991 and is located at the Matam Advanced
Technology Center in Haifa, Israel. Since its
founding, TEIC has been chosen several times as
Israel's leading incubator based on its achievements
in promoting start-ups and creating value for its
companies. .
|
 |
|
GeneGrafts
www.genegrafts.com
is a new
biotechnology company, developing a novel therapy
for atrial fibrillation (AF). Atrial fibrillation is
the most common cardiac arrhythmia affecting 2
million Americans. Conventional therapy for AF is
based on medications taken daily, with significant
side effects. GeneGrafts is developing a
transkaryotic approach using autologous (extracted
from the patient) genetically modified cells that
are delivered to the patient’s heart by
catheterization. The treatment is localized and
involves a single procedure.
|
|
 |
|
BioControl
can detect,
isolate and treat variety of diseases and symptoms
using (i) unidirectional selective neuromodulation
of nerve signals, and (ii) coupling therapy to
sensorial input.The Company’s first product aims to
treat incontinence of all types: over active bladder
(OAB), mix (combined stress and OAB), and
interstitial cystitis (IC). BioControl has so far
implanted 50 patients in its ongoing clinical trials
and results are very promising. Treatment of
congestive heart failure is BioControl’s second area
of focus. Using its unidirectional selective
neuromodulation technique to stimulate the vagus
nerve, BioControl aims to reduce stress of the heart
muscle by lowering heart rate. The technique allows
for reduced muscle stress while increasing cardiac
output when necessary. The CardioFit implantable
device is in preclinical studies being tested in a
chronically sick animal model at the Henry Ford
Institute in Detroit with promising initial results.
Back to Top
|
 |
|
F.D. Cardio. has invented
a unique technology platform to facilitate catheter
use for interventional cardiology, interventional
neurology and others, with pushing force and
maneuverability capabilities in the front distal
therapeutic part of the catheter. It will provide
interventional cardiologists and interventional
neurologists with a powerful new range of catheters
equipped with front maneuvering capabilities – new
phenomena that till now have not been available in
the market. The new delivery system will permit
surgeons to reach and to treat currently unreachable
blood vessel lesions/sites.
|
 |
|
Colbar
www.colbar.com
develops and
manufactures a range of innovative tissue
engineering products based on its patented
cross-linked collagen technology. Using this
breakthrough technology, Colbar can develop products
with longevity and degradation rates programmed to
meet specific clinical needs. Colbar’s products
closely mimic natural human cross-linked collagen, a
key biological polymer that provides structure and
strength, and supports the function of most human
tissues and organs.
Acquired by a division of Johnson & Johnson (NYSE:JNJ)
|
|
|
|
Regentis Biomaterials, Ltd.
www.regentis.co.il
is a medical material development company that is
focused on commercializing its patent-applied Gelrin
Platform Technology for bone, spine and cartilage
repair.
Back to Top |
